Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
October 14, 2023
Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice
Daniel H O' Donovan, David Baker, Giovanni Ciotta, et al.
Journal of Medicinal Chemistry
|
June 14, 2012
Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017)
James S Scott, Suzanne S Bowker, Joanne Deschoolmeester, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 8, 2021
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase
Daniel H O' Donovan, Clare Gregson, Martin J Packer, et al.
Journal of Medicinal Chemistry
|
July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
Sharan K Bagal, Peter C Astles, Coura Diène, et al.
Journal of Medicinal Chemistry
|
May 21, 2024
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations
Clare Thomson, Peter Barton, Erin Braybrooke, et al.
Cell Reports. Medicine
|
August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Aisha M Swaih, Sara Talbot, Adriana Savoca, et al.
Science Translational Medicine
|
May 1, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors
Erica Banks, Michael Grondine, Deepa Bhavsar, et al.
Journal of Medicinal Chemistry
|
September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
Jason G Kettle, Rana Anjum, Evan Barry, et al.
Journal of Medicinal Chemistry
|
September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
Clare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Journal of Medicinal Chemistry
|
January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
James S Scott, Laura Evans, Peter C Astles, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Bioorganic & Medicinal Chemistry Letters
|
October 14, 2023
Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice
Daniel H O' Donovan, David Baker, Giovanni Ciotta, et al.
Journal of Medicinal Chemistry
|
June 14, 2012
Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017)
James S Scott, Suzanne S Bowker, Joanne Deschoolmeester, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 8, 2021
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase
Daniel H O' Donovan, Clare Gregson, Martin J Packer, et al.
Journal of Medicinal Chemistry
|
July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
Sharan K Bagal, Peter C Astles, Coura Diène, et al.
Journal of Medicinal Chemistry
|
May 21, 2024
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations
Clare Thomson, Peter Barton, Erin Braybrooke, et al.
Cell Reports. Medicine
|
August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Aisha M Swaih, Sara Talbot, Adriana Savoca, et al.
Science Translational Medicine
|
May 1, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors
Erica Banks, Michael Grondine, Deepa Bhavsar, et al.
Journal of Medicinal Chemistry
|
September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
Jason G Kettle, Rana Anjum, Evan Barry, et al.
Journal of Medicinal Chemistry
|
September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
Clare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Journal of Medicinal Chemistry
|
January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
James S Scott, Laura Evans, Peter C Astles, et al.
Page
of 5